The patient was a 41-year-old Japanese female who had been diagnosed with breast cancer, and chemotherapy for breast cancer-related AML. She underwent allogeneic HSCT using cord blood units, but AML relapsed on day 153. Next, she underwent allogeneic HSCT from her HLA-haploidentical sister on day 236 after cord blood transplantation. Complete second donor chimerism was confirmed in the fractions of mononuclear cells and granulocytes of peripheral blood on days 15, 19 and 22 after the second HSCT. She achieved CR and was discharged. However, AML relapsed again on day 64 after second HSCT. Comparing the merits and demerits of best supportive therapy, she and her family desired the curative option, and she was enrolled in the clinical trial of HLA fully mismatched (both HLA-haplotype mismatched) transplantation (UMIN000008117), in which the only candidate for a third HSCT was her cousin. The HLA profiles of the recipient and third donor were HLA-A*24:02/26:02 B*15:01/54:01 C*01:02/ 03:03 DRB1*04:05/14:06 and HLA-A*11:01/24:02 B*39:04/40:02 C*03:04/07:02 DRB1*09:01/14:54, respectively. Although she did not have any HLA antibodies before her second HSCT, a workup for the third HSCT revealed that she had a high titer of HLA antibodies, presumably produced by transfusions after the second HSCT. The most prominent DSA was anti-HLA B*40:02, the titer of which was 8103 on admission. To ensure engraftment, we attempted the desensitization of DSA prior to the HSCT, consisting of a single dose of rituximab 375 mg/m 2 on day − 10, IVIg 5 g/day for 4 days (day − 8 to − 5) and 20 units of DSA-PC transfusion (6 h prior to the infusion of the HSCT). The donor of the platelet transfusion was a healthy-related donor (another cousin, the sister of the third donor) who had identical HLA with the third transplant donor. Platelets were collected with an ordinal procedure using COBE spectra (Terumo BCT, Tokyo, Japan). The final volume of the platelet concentrates was 324 mL, containing 3.86 × 10 11 platelets. A reduced intensity conditioning regimen was used consisting of 30 mg/m 2 /day of fludarabine for 6 days (days − 8 to − 3), 100 mg/body/day of continuous IV Ara-C for 5 days (days − 8 to − 4), 3.2 mg/kg/day of IV busulfan for 2 days (days − 3 and − 2) and 0.83 mg/kg/day of rabbit anti-thymocyte globulin (Thymoglobulin, Sanofi, Tokyo, Japan) for 3 days (days − 3 to − 1). Prophylaxis for GvHD consisted of the continuous infusion of tacrolimus with a target concentration of 9-11 ng/mL starting from day − 2, and 1 mg/kg/day of methylprednisolone starting from day 0. Fifteen mg/kg/day of mycophenolate mofetil was administered after engraftment (from day 13) and discontinued on day 38. PBSC were transplanted on day 148 after the second HSCT. She received G-CSF from day 3 to the day of neutrophil engraftment. Consequently, she did not require additional platelet transfusion from days − 0 to 2. Donor neutrophil engraftment was successfully achieved, with an absolute neutrophil count 40.5 × 10 9 /L on day 9 after transplantation. Complete donor-type chimerism in the peripheral blood was confirmed on days 9 and 17. Acute skin GvHD developed on day 54, and subsided on day 66 by a transient increase of immunosuppressive drugs. The patient has been followed as an outpatient, maintaining CR as of 12 months after the third HSCT.
MFI of DSA (anti-HLA B*40:02 Ab) before and after the administration of rituximab was 5562 and 4136, respectively, which suggests that the reducing effect of rituximab was modest. IVIg did not affect the titer of HLA antibodies at all, as theoretically expected. The preconditioning regimen of HSCT consisting of fludarabine, Ara-C, busulfan and anti-thymocyte globulin slightly reduced the titer of DSA to 2926 just before DSA-PC transfusion. Then, we performed the DSA-PC transfusion for 3 h on day 0. Surprisingly, the serum MFI level was reduced to 267 at the end of the DSA-PC transfusion (Figure 1) . Furthermore, DSA-PC transfusion resulted in a reduction of not only the titer of DSA (anti-HLA B*40:02 Ab), but also the titers of all other high-titer HLA antibodies. The titer of DSA and all other HLA antibodies did not rise again until day 14 after the HSCT.
HLA epitope registry data revealed that almost all of the high-MFI HLA antibodies were those that recognize HLA class I containing an epitope, 163EW (163EW(+)-HLA), which was shared with the DSA-targeted HLA B*40:02. 163EW is known as a highly reactive epitope in platelet refractoriness. 11 The serum levels of MFI just before the transfusion of DSA-PC are aligned in order of decreasing height in Figure 2 . Among the 22 kinds of HLA antibodies targeting 163EW(+)-HLA we checked, 17 HLA antibodies had an MFI of more than 1000 (Figure 2, left panel) . On the other hand, the MFI of HLA antibodies targeting HLA not containing epitope 163EW (163EW(−)-HLA) were within the negligible range (MFI o1000). The top 30 HLA antibodies targeting 163EW(−)-HLA were aligned as control examples (Figure 2, right panel) . Lachmann et al. 12 reported that 'HLA Ab specificity is more appropriately described by the corresponding epitope rather than the HLA Ag'. The HLA antibodies in fact recognize an epitope contained in HLA molecules, and one HLA Ab may react with multiple HLAs sharing the same epitope. Therefore, the mechanism of DSA-PC to reduce all high-titer HLA antibodies seems to be a direct absorption of anti-163EW epitope antibodies. According to this theory, even a transfusion of platelets expressing HLA sharing the epitope with DSA-targeted HLA (not DSA-PC itself) may be beneficial. If the targeted epitope is a common one, platelets from a random donor may contain the epitope, and the HLA antibodies may be absorbed following a random platelet transfusion. However, the titer of the HLA antibodies may be restored by the de novo production of HLA antibodies. If so, a B-cell-depleting agent, such as rituximab, should be added to the desensitization protocol to cut off the supply of newly produced HLA antibodies. This theory should be validated.
The limitation of DSA-PC is that it cannot be used in HLA antibodies against HLA class II molecules, because platelets do not express HLA class II. For HLA class II antibodies, buffy coat transfusion bearing the targeted HLA may be available. 7, 13 Regrettably, we did not have the opportunity to check the C′ level in this case, which was reported to play a role in HLA Ab-mediated graft failure. In conclusion, the combination of rituximab and DSA-PC reduced the titers of DSA and epitope-shared HLA antibodies. Further experience should be accumulated to confirm the efficacy of this method.
